- Home
- LPTX vs AGEN Comparison
LPTX vs AGEN Comparison
Compare LPTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- AGEN
- Stock Information
- Founded
- LPTX 2011
- AGEN 1994
- Country
- LPTX United States
- AGEN United States
- Employees
- LPTX N/A
- AGEN N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPTX Health Care
- AGEN Health Care
- Exchange
- LPTX Nasdaq
- AGEN Nasdaq
- Market Cap
- LPTX 99.5M
- AGEN 96.2M
- IPO Year
- LPTX N/A
- AGEN 2000
- Fundamental
- Price
- LPTX $3.11
- AGEN $2.92
- Analyst Decision
- LPTX Strong Buy
- AGEN Buy
- Analyst Count
- LPTX 3
- AGEN 3
- Target Price
- LPTX $7.50
- AGEN $10.50
- AVG Volume (30 Days)
- LPTX 437.3K
- AGEN 551.7K
- Earning Date
- LPTX 11-13-2024
- AGEN 11-12-2024
- Dividend Yield
- LPTX N/A
- AGEN N/A
- EPS Growth
- LPTX N/A
- AGEN N/A
- EPS
- LPTX N/A
- AGEN N/A
- Revenue
- LPTX N/A
- AGEN $160,427,000.00
- Revenue This Year
- LPTX N/A
- AGEN N/A
- Revenue Next Year
- LPTX N/A
- AGEN $36.13
- P/E Ratio
- LPTX N/A
- AGEN N/A
- Revenue Growth
- LPTX N/A
- AGEN 59.00
- 52 Week Low
- LPTX $1.68
- AGEN $2.50
- 52 Week High
- LPTX $5.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- LPTX 51.79
- AGEN 41.32
- Support Level
- LPTX $2.87
- AGEN $2.73
- Resistance Level
- LPTX $3.12
- AGEN $3.85
- Average True Range (ATR)
- LPTX 0.28
- AGEN 0.29
- MACD
- LPTX 0.02
- AGEN -0.01
- Stochastic Oscillator
- LPTX 49.42
- AGEN 24.03
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).